Check our first Journal Impact Factor

Important announcement Can't see this email properly? [Click here to view an online version]( [EBioMedicine]( Important announcement [Register now]( [cover]( Dear colleague, We are delighted to announce that EBioMedicine, published by The Lancet, has received its first [Journal Impact Factor of 6·183]( (2017 Journal Citation Reports®, Clarivate Analytics 2018). This measure underlines EBioMedicine's position as a premium open access venue for translational biomedical research. Thank you We thank all our authors, readers, reviewers, advisory board members, and supporters for their invaluable contribution. Stay up to date Register for free to receive regular content alerts from EBioMedicine. [Register now]( [Twitter]( This message has been sent to {EMAIL} from Elsevier Communications on behalf of The Lancet. If you no longer wish to receive messages of this nature from us in the future, please [click here](. Visit the [Elsevier Preference Center]( to manage more of your communication preferences with us. Copyright © 2018 [Elsevier B.V.](. All rights reserved. | [Elsevier Privacy Policy]( Elsevier B.V. Registered Office: Radarweg 29, 1043 NX Amsterdam, The Netherlands. Reg. No. 33158992 – Netherlands. VAT No. NL 005033019B01.